<DOC>
	<DOCNO>NCT02700568</DOCNO>
	<brief_summary>Aim FavorAx study evaluate preliminary efficacy safety Axitinib metastatic renal cell carcinoma patient favorable IMDC prognostic factor progress sunitinib pazopanib first-line setting .</brief_summary>
	<brief_title>Axitinib Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors</brief_title>
	<detailed_description>Axitinib tyrosine kinase inhibitor vascular endothelial growth factor receptor , platelet-derived growth factor receptor-Î± , c-kit . The trial comparative effectiveness axitinib versus sorafenib advance renal cell carcinoma ( AXIS ) international randomized Phase III study design registration purpose . This trial randomize 723 metastatic renal cell carcinoma patient prognostic feature axitinib sorafenib second-line setting demonstrate significant clinical benefit axitinib . Aim present FavorAx study evaluate preliminary efficacy safety Axitinib metastatic renal cell carcinoma patient favorable IMDC prognostic factor progress sunitinib pazopanib first-line setting .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Principle Histologic confirmation Renal cell carcinoma clear cell component Patients must measurable disease Previous treatment sunitinib pazopanib Favorable prognosis accord IMDC criterion Must available tumor tissue submission Subjects must also meet various laboratory parameter inclusion Patients must give write informed consent prior initiation therapy Any underlying medical condition , opinion Investigator , make administration study drug hazardous obscure interpretation adverse event Patients history uncompensated disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>